US equities |
NVDA $173.73 ▲+0.00% AMD $552.90 ▲+0.00% MU $811.30 ▲+0.00% SNDK $977.69 ▲+0.00% NBIS $154.69 ▲+0.00% SPCX $139.75 ▲+0.00% AVGO $345.22 ▲+0.00% BABA $101.52 ▲+0.00%
FinancialContent

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

7.480 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MapLight Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conference
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Premarket Movers on Oct. 20, 2026: Gainers and Losers ↗
Via Chartmill
News headline image
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conference
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces $150 Million Private Placement Financing
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant... 
Via MarketBeat
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >